GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks

Completed

Conditions: Depressive Disorder, Major

Interventions: Other: KAB survey

First Posted Date: 2016-12-23

Last Posted Date: 2018-02-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT03001440

Study of GSK2586881 on Acute Hypoxia and Exercise

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Biological: GSK2586881
Other: Placebo

First Posted Date: 2016-12-22

Last Posted Date: 2019-12-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 17

Registration Number: NCT03000686

Locations: 🇩🇪
GSK Investigational Site, Hannover, Niedersachsen, Germany

Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women

Phase 1

Terminated

Conditions: Postpartum Hemorrhage

Interventions: Drug: IH Oxytocin
Drug: IM Oxytocin
Device: ROTAHALER
Drug: IV Oxytocin

First Posted Date: 2016-12-21

Last Posted Date: 2020-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 31

Registration Number: NCT02999100

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Efficacy of Three Experimental Toothpastes to Remove Plaque

Not Applicable

Completed

Conditions: Dental Plaque

Interventions: Drug: 20% w/w sodium bicarbonate
Drug: 35% w/w sodium bicarbonate
Drug: 50% w/w sodium bicarbonate
Drug: 67% w/w sodium bicarbonate
Drug: 0% w/w sodium bicarbonate

First Posted Date: 2016-12-14

Last Posted Date: 2019-05-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 75

Registration Number: NCT02992691

Locations: 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Budesonide (BUD) Turbuhaler
Drug: Fluticasone furoate (FF) Dry Powder Inhaler
Drug: Fluticasone propionate (FP) Dry Powder Inhaler
Drug: Placebo (ELLIPTA or DISKUS)

First Posted Date: 2016-12-14

Last Posted Date: 2020-07-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 56

Registration Number: NCT02991859

Locations: 🇬🇧
GSK Investigational Site, Manchester, United Kingdom

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Phase 2

Completed

Conditions: Neoplasms

Interventions: Drug: letetresgene autoleucel (GSK3377794)
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2016-12-14

Last Posted Date: 2023-04-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23

Registration Number: NCT02992743

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children

Phase 4

Completed

Conditions: Virus Diseases

Interventions: Procedure: Blood draw

First Posted Date: 2016-12-14

Last Posted Date: 2017-04-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 150

Registration Number: NCT02991872

Locations: 🇨🇳
GSK Investigational Site, Mengshan, China

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)

First Posted Date: 2016-12-08

Last Posted Date: 2019-11-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 704

Registration Number: NCT02986854

Locations: 🇵🇷
GSK Investigational Site, Ponce, Puerto Rico

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection

Phase 2

Completed

Conditions: Hepatitis B
Chronic Hepatitis B Atypical

Interventions: Drug: Placebo
Drug: IONIS-HBVRx

First Posted Date: 2016-12-05

Last Posted Date: 2021-08-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 31

Registration Number: NCT02981602

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 4 locations

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Device: Placebo ELLIPTA
Device: Placebo DISKUS
Device: Placebo TURBUHALER
Device: Placebo HANDIHALER
Other: PQ3
Other: PQ4
Other: PQ1
Other: PQ2

First Posted Date: 2016-12-05

Last Posted Date: 2019-10-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 160

Registration Number: NCT02982187

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Home Terms & Conditions Privacy Policy